Susie Tappouni
407-238-4020 or 407-238-4021
susie.tappouni@asco.org
ALEXANDRIA, Va. – In addition to the abstracts presented in the 2011 Genitourinary Cancers Symposium Presscast, seven noteworthy studies on the prevention, screening, evaluation and management of genitourinary cancers were highlighted by the co-sponsoring organizations of this year’s Symposium. The 2011 Genitourinary Cancers Symposium is being held February 17-19 at the Orlando World Center Marriott in Orlando, FL.
Abstract 3
A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013.
General Session II
Lead Author: Laurence Klotz, MD
Thursday, February 17
11:00 – 11:10 AM ET
Abstract 4
Improved survival outcomes in clinically relevant patient subgroups from COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-based chemotherapy.
General Session II
Lead Author: Howard Scher, MD
Thursday, February 17
11:10 – 11:20 AM ET
Abstract 10
PSA response and early PSA progression evaluated in patients randomized in a phase III trial comparing androgen-deprivation therapy (ADT) plus docetaxel versus ADT alone in hormone-naive metastatic prostate cancer (GETUG-AFU 15/0403).
Oral Abstract Session A
Lead Author: Gwenaelle Gravis, MD
Thursday, February 17
1:30 – 1:40 PM ET
Abstract 11
A phase II study of pomegranate extract for men with rising prostate-specific antigen following primary therapy.
Oral Abstract Sessison A
Lead Author: Michael Carducci, MD
Friday, February 18
1:40 – 1:50 PM ET
Abstract 64
Gastrointestinal toxicities following radiation therapy for localized prostate cancer.
General Poster Session A
Lead Author: Grace Lu-Yao, MD
Thursday, February 17
A 54
Abstract 120
Inappropriate utilization of radiographic imaging in men with newly diagnosed prostate cancer.
General Poster Session B
Lead Author: Sandip Prasad, MD
Thursday, February 17
A 14
Abstract 127
Phase II study of XL184 in a cohort of patients with castration-resistant prostate cancer and measurable soft tissue disease.
General Poster Session B
Lead Author: David C. Smith, MD
Thursday, February 17
A 21
Relevant Links on ASCO’s Patient Website, Cancer.Net:
- Guide to Prostate Cancer
- Guide to Bladder Cancer
- ASCO Answers: Bladder Cancer
- What to Know: ASCO’s Guideline on Hormone Therapy for Advanced Prostate Cancer
- After Treatment for Prostate Cancer: Managing Side Effects
- Understanding Chemotherapy
- Understanding Radiation Therapy
- Complementary and Alternative Medicine
To view the full tip sheet and abstracts, please click here.
